Variable | Univariate | Multivariate | ||
HR (95% CI) | p-value | HR (95% CI) | p-value | |
Age, years | 0.997 (0.971 to 1.024) | 0.837 | Not Included | |
Positive lymph node, number | 1.089 (1.049 to 1.131) | <0.001 | 1.093 (1.048 to 1.140) | <0.001 |
Tumor size, cm | 1.462 (1.117 to 1.816) | 0.001 | 1.368 (1.085 to 1.724) | 0.008 |
HRD score | 0.997 (0.989 to 1.006) | 0.525 | Not Included | |
PAM50 | ||||
Basal | Ref | Not Included | ||
Others | 1.375 (0.749 to 2.524) | 0.304 | ||
Tumor HLA-I LOH | ||||
LOH | Ref | Ref | ||
Non-LOH | 0.459 (0.245 to 0.860) | 0.015 | 0.307 (0.158 to 0.596) | <0.001 |
TNBC immune subtype | ||||
Immune-inflamed | Ref | Ref | ||
Non-immune-inflamed | 2.519 (1.067 to 5.946) | 0.035 | 2.784 (1.169 to 6.629) | 0.033 |
HRs and p-values of the covariates in the univariate and multivariate Cox proportional hazard models for RFS.
CI, confidence interval; HLA, human leukocyte antigen; HRD, homologous recombination deficiency; LOH, loss of heterozygosity; RFS, relapse-free survival; TNBCs, triple-negative breast cancers.